Your browser doesn't support javascript.
loading
Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.
Ricciuti, Biagio; Arbour, Kathryn C; Lin, Jessica J; Vajdi, Amir; Vokes, Natalie; Hong, Lingzhi; Zhang, Jianjun; Tolstorukov, Michael Y; Li, Yvonne Y; Spurr, Liam F; Cherniack, Andrew D; Recondo, Gonzalo; Lamberti, Giuseppe; Wang, Xinan; Venkatraman, Deepti; Alessi, Joao V; Vaz, Victor R; Rizvi, Hira; Egger, Jacklynn; Plodkowski, Andrew J; Khosrowjerdi, Sara; Digumarthy, Subba; Park, Hyesun; Vaz, Nuno; Nishino, Mizuki; Sholl, Lynette M; Barbie, David; Altan, Mehmet; Heymach, John V; Skoulidis, Ferdinandos; Gainor, Justin F; Hellmann, Matthew D; Awad, Mark M.
Afiliación
  • Ricciuti B; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Arbour KC; Department of Medicine, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Lin JJ; Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
  • Vajdi A; Department of Analytics and Informatics, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Vokes N; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Hong L; Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Zhang J; Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Tolstorukov MY; Department of Analytics and Informatics, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Li YY; Department of Analytics and Informatics, Dana-Farber Cancer Institute, Boston, Massachusetts; Cancer Program, Broad Institute of Harvard and Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts.
  • Spurr LF; Department of Analytics and Informatics, Dana-Farber Cancer Institute, Boston, Massachusetts; Cancer Program, Broad Institute of Harvard and Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts.
  • Cherniack AD; Department of Analytics and Informatics, Dana-Farber Cancer Institute, Boston, Massachusetts; Cancer Program, Broad Institute of Harvard and Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts.
  • Recondo G; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Lamberti G; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Wang X; Harvard Graduate School of Arts and Sciences, Harvard University, Cambridge, Massachusetts; Department of Environmental Health, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts.
  • Venkatraman D; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Alessi JV; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Vaz VR; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Rizvi H; Department of Medicine, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Egger J; Department of Medicine, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Plodkowski AJ; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Khosrowjerdi S; Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
  • Digumarthy S; Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
  • Park H; Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts.
  • Vaz N; Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts.
  • Nishino M; Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts.
  • Sholl LM; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
  • Barbie D; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Altan M; Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Heymach JV; Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Skoulidis F; Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Gainor JF; Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
  • Hellmann MD; Department of Medicine, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Awad MM; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Electronic address: mark_awad@dfci.harvard.edu.
J Thorac Oncol ; 17(3): 399-410, 2022 03.
Article en En | MEDLINE | ID: mdl-34740862
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteínas Proto-Oncogénicas p21(ras) / Proteína 1 Asociada A ECH Tipo Kelch / Adenocarcinoma del Pulmón / Quinasas de la Proteína-Quinasa Activada por el AMP / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Thorac Oncol Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteínas Proto-Oncogénicas p21(ras) / Proteína 1 Asociada A ECH Tipo Kelch / Adenocarcinoma del Pulmón / Quinasas de la Proteína-Quinasa Activada por el AMP / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Thorac Oncol Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos